Head-To-Head Review: Innate Pharma (NASDAQ:IPHA) & Oncolytics Biotech (NASDAQ:ONCY)

Innate Pharma (NASDAQ:IPHA) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Innate Pharma and Oncolytics Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1	1	1	1	2.50
Oncolytics Biotech	1	0	2	1	2.75

Innate Pharma currently has a consensus price target of $5.00, indicating a potential upside of 184.09%. Oncolytics Biotech has a consensus price target of $8.50, indicating a potential upside of 902.00%. Given Oncolytics Biotech’s stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Innate Pharma.

Risk and Volatility

Innate Pharma has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Valuation and Earnings

This table compares Innate Pharma and Oncolytics Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19 million	16.22	-$55.64 million	N/A	N/A
Oncolytics Biotech	N/A	N/A	-$28.76 million	($0.31)	-2.74

Oncolytics Biotech has lower revenue, but higher earnings than Innate Pharma.

Profitability

This table compares Innate Pharma and Oncolytics Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Institutional and Insider Ownership

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Oncolytics Biotech beats Innate Pharma on 6 of the 10 factors compared between the two stocks.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.